Breaking Finance News

Zafgen Inc (NASDAQ:ZFGN) target price upped to $4.00, released a report earlier today by Zacks Investment Research

Just yesterday Zafgen Inc (NASDAQ:ZFGN) traded 2.10% higher at $3.59. Zafgen Inc’s 50-day moving average is $3.50 and its 200-day moving average is $4.08. The last stock price is down -16.76% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.05% over the same time period. 79,526 shares of ZFGN traded hands, down from an average trading volume of 201,867

Stating a potential upside of 0.11%, Zacks Investment Research increased the stock price target of Zafgen Inc (NASDAQ:ZFGN) to $4.00

Recent Performance Chart

Zafgen Inc (NASDAQ:ZFGN)

Zafgen Inc has 52 week low of $2.89 and a 52 week high of $5.46 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokers have released a ratings update on ZFGN. The one year target is $22.14 with two brokerages rating the company a strong buy, two brokerages rating the company a buy, three analysts rating the company a hold, zero brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Zafgen Inc (NASDAQ:ZFGN)

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.